The first blood thinning drug to be approved in more than five decades for stroke patients has been launched in Britain and is expected to help more than 1.2 million patients in the country.
Recently concluded trial studies of the drug dabigatran etexilate, which will be marketed as Pradaxa, have shown that it reduces the risk of stroke by almost 39 percent among patients suffering from atrial fibrillation.
Experts believe that while Pradaxa is considerably more expensive than the currently available drug warfarin, it is more effective than the latter and there is no danger of accidently giving the wrong dose.
"This new medication appears to be very promising. However, it's important to note that it won't be suitable for all, and every AF patient needs to be treated on a case-by-case basis to ensure that they receive the best possible treatment for them", Chief executive of the Stroke Association, Jon Barrick said.